Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 8 de 8
Filtrar
1.
J Med Virol ; 96(8): e29853, 2024 Aug.
Artículo en Inglés | MEDLINE | ID: mdl-39135474

RESUMEN

This study aimed to retrospectively evaluate the baseline and follow-up viral loads and viral clearance times in cases followed for asymptomatic and symptomatic congenital cytomegalovirus (cCMV) infection between August 2010 and August 2022. Among 93 cases, they had asymptomatic (n: 55) and symptomatic (n: 38). The median baseline blood viral load detected in the symptomatic cCMV (ScCMV) infection (13 054 IU/mL) was significantly higher than that of asymptomatic cCMV (AcCMV) infection (4636 IU/mL) (p < 0.013). There was no difference in median viral clearance times (75 and 90 days, respectively) in baseline viremic cases in the ScCMV and AcCMV infection groups. There were no differences in median baseline blood viral load (6930 IU/mL and 14 268 IU/mL, respectively) and median viral clearance times (75 and 85 days, respectively) between the 6-week and 6-month antiviral treatment group. No correlation was found between baseline blood viral load, clinical severity, and the number of systems involved. However, in initial viremic cases, the viral load threshold for a symptomatic case was 8856 IU/mL, with 85.7% sensitivity and 54.5% specificity.


Asunto(s)
Infecciones por Citomegalovirus , Citomegalovirus , Carga Viral , Humanos , Infecciones por Citomegalovirus/congénito , Infecciones por Citomegalovirus/virología , Infecciones por Citomegalovirus/sangre , Infecciones por Citomegalovirus/diagnóstico , Estudios Retrospectivos , Femenino , Masculino , Recién Nacido , Citomegalovirus/aislamiento & purificación , Citomegalovirus/genética , Infecciones Asintomáticas , Lactante , Antivirales/uso terapéutico , Viremia/virología
2.
J Trop Pediatr ; 70(5)2024 Aug 10.
Artículo en Inglés | MEDLINE | ID: mdl-39231448

RESUMEN

Current data on fosfomycin usage in children are limited. We present data on the clinical use of intravenous (IV) fosfomycin in children. Hospitalized patients who received ≥3 days of IV fosfomycin between April 2021 and March 2023 were analyzed retrospectively. Forty-three episodes of infection in 39 patients were evaluated. The mean age of the patients was 5.35 (10 days to 17.5 years) years, and 54% were male. Infections were hospital-acquired in 79% of the episodes. Indications for fosfomycin were urinary tract infection (35%), bacteremia (32.6%), catheter-related bloodstream infection (16.3%), soft tissue infection (4.7%), sepsis (4.7%), surgical site infection (2.3%), burn infection (2.3%), and pneumonia (2.3%). Klebsiella pneumoniae was identified in 46.5% of the episodes, and a pan-drug or extensive drug resistance was detected in 75% of them. Carbapenem was used before fosfomycin at significantly higher rates in K. pneumoniae episodes (P = .006). Most (88.5%) patients received fosfomycin as a combination therapy. Culture negativity was achieved in 80% of episodes within a median treatment period of 3 (2-22) days, which was significantly shorter in K. pneumoniae episodes (P < .001). Treatment-related side effects were seen in 9.3% of the episodes. Side effects were significant after 3 weeks of treatment (P = .013). The unresponsivity rate to fosfomycin was 23.3%. Nine (21%) of the patients who were followed up in the intensive care units mainly died because of sepsis (56%). IV fosfomycin is an effective agent in treating severe pediatric infections caused by resistant microorganisms. Fosfomycin can be used in various indications and is generally safe for children.


Asunto(s)
Administración Intravenosa , Antibacterianos , Bacteriemia , Fosfomicina , Humanos , Fosfomicina/administración & dosificación , Fosfomicina/uso terapéutico , Masculino , Femenino , Antibacterianos/administración & dosificación , Antibacterianos/uso terapéutico , Niño , Estudios Retrospectivos , Turquía , Lactante , Adolescente , Preescolar , Resultado del Tratamiento , Bacteriemia/tratamiento farmacológico , Recién Nacido , Klebsiella pneumoniae/efectos de los fármacos , Klebsiella pneumoniae/aislamiento & purificación , Infección Hospitalaria/tratamiento farmacológico , Sepsis/tratamiento farmacológico , Infecciones Urinarias/tratamiento farmacológico , Infecciones por Klebsiella/tratamiento farmacológico
3.
J Trop Pediatr ; 69(1)2022 12 05.
Artículo en Inglés | MEDLINE | ID: mdl-36548396

RESUMEN

OBJECTIVE: This study aimed to determine whether parental vaccination against coronavirus disease 2019 (COVID-19) prevents hospitalization of COVID-19-infected children. METHODS: This study was based on data obtained from the records of pediatric patients that were followed up for virologically proven COVID-19 infection between August and October 2021, during which time the delta variant was dominant in Turkey and the children were isolating at home. RESULTS: There were 151 patients in the inpatient group and 218 in the outpatient group; the mean age was 172.5 and 145.5 months in the groups, respectively. The rates of obesity (22.5% and 6.4%, respectively, p < 0.001) and neurological-neurodevelopmental disorders (8.6% and 1.4%, respectively, p < 0.001) were significantly higher in the inpatient group than in the outpatient group. Of the outpatients' parents, 67.4% (n = 147) were fully vaccinated vs. 38.4% (n = 58) in the inpatient group. In all, 39.7% (n = 60) of the inpatients' parents were unvaccinated vs. 18.3% (n = 40) in the outpatient group. There was a significant correlation between the vaccination status and the patient groups (p < 0.001); it was determined that the COVID-19 infection would be mild in children if both parents were fully vaccinated. When both parents were fully vaccinated against COVID-19, the hospitalization rate decreased and the outpatient follow-up rate increased. CONCLUSION: Having both parents fully vaccinated against COVID-19 can indirectly protect their subsequently infected children from hospitalization and the long-term effects of infection. Nonetheless, more comprehensive research on delta and non-delta variants is needed.


Asunto(s)
COVID-19 , Humanos , Niño , COVID-19/epidemiología , COVID-19/prevención & control , SARS-CoV-2 , Pacientes Ambulatorios , Hospitalización , Vacunación
4.
J Trop Pediatr ; 63(1): 4-9, 2017 02.
Artículo en Inglés | MEDLINE | ID: mdl-27388618

RESUMEN

OBJECTIVE: We aimed to develop a transcutaneous bilirubin (TcB) nomogram for assessment of the risk of significant hyperbilirubinemia and prolonged jaundice during the first month of life in term and late-preterm Turkish newborns. METHODS: On the basis of the daily (3rd, 7th, 15th and 30th days) TcB measurements, 3rd, 10th, 25th, 50th, 75th, 90th and 97th percentiles, and 5 percentile tracks were obtained. TcB measurements were made by a transcutaneous bilirubinometer (JaundiceDetector JH20-1C). RESULTS: We screened 729 healthy term and late-preterm Turkish infants 3-30 days old and developed a nomogram of TcB levels. TcB level was ≥5 mg/dl in 41.98% and 25.9% of infants at age 15.0 ± 2.1 days and 30.9 ± 2.6 days, respectively. The TcB measurement-based nomogram values of the 97th percentiles (cutoff values) at age 15.0 ± 2.1 and 30.9 ± 2.6 days were 11.4 (10.82-12.13) mg/dl and 10.0 (9.40-10.70) mg/dl, respectively. CONCLUSION: This nomogram can be used to determine the risk status of Turkish newborns regarding significant hyperbilirubinemia and prolonged jaundice on the basis of TcB measurement in the first month of life.


Asunto(s)
Bilirrubina/sangre , Hiperbilirrubinemia Neonatal/diagnóstico , Enfermedades del Prematuro/diagnóstico , Tamizaje Neonatal/métodos , Nomogramas , Biomarcadores/sangre , Femenino , Estudios de Seguimiento , Humanos , Hiperbilirrubinemia Neonatal/sangre , Recién Nacido , Recien Nacido Prematuro , Enfermedades del Prematuro/sangre , Masculino
5.
Pediatr Infect Dis J ; 43(7): e231-e234, 2024 Jul 01.
Artículo en Inglés | MEDLINE | ID: mdl-38621150

RESUMEN

BACKGROUND: Herbaspirillum species are nonfermenting, aerobic, helical or curved, Gram-negative bacteria belonging to the class Betaproteobacteria, order Burkholderiales. To date, only a few studies have reported on the epidemiology, clinical symptoms, antibiotic susceptibility profiles, treatment and outcomes of Herbaspirillum huttiense -related infections in pediatric patients. METHODS: The aim of this study was to present 3 years of H.huntiense data, antibiotic susceptibility profiles, systemic antibiotics and antibiotic lock therapy (ALT) options and clinical outcomes. RESULTS: Fourteen episodes of infection in 12 patients were included in this retrospective study. The patients had a male/female ratio of 1:1 and a median age of 160.5 months (range, 3-198 months). Catheter-related bloodstream infection (CRBSI) was detected in 11 patients. Only 1 patient developed catheter-related infective endocarditis. The patient's catheter was removed, and she was successfully treated with systemic antibiotics for 4 weeks. Systemic antibiotics were used in all infections related to H. huttiense . In septic, critically ill patients, the catheter was removed, and systemic antibiotics were started. Port catheters were removed in 5 patients. ALT was performed in clinically stable patients. ALT using amikacin was administered to 6 patients through the port catheter. Two patients had a 2nd attack. After the 2nd ALT treatment, 1 patient cured, and the catheter of the other patient was removed due to persistent microbial growth in cultures. Antimicrobial susceptibility testing of the reported isolates showed susceptibility to meropenem (90%), ceftazidime (87%) and piperacillin/tazobactam (65%), with 92% resistance to colistin. CONCLUSION: H. huttiense is an emerging pathogen in CRBSI. Piperacillin/tazobactam, ceftazidime and meropenem appear to be good therapeutic options for the treatment of H. huttiense infections. ALT and systemic antibiotics can be used in H. huttiense -CRBSI to sterilize and preserve the central venous catheter.


Asunto(s)
Antibacterianos , Infecciones Relacionadas con Catéteres , Infecciones por Bacterias Gramnegativas , Herbaspirillum , Pruebas de Sensibilidad Microbiana , Humanos , Femenino , Masculino , Niño , Estudios Retrospectivos , Antibacterianos/uso terapéutico , Antibacterianos/farmacología , Herbaspirillum/efectos de los fármacos , Herbaspirillum/genética , Infecciones Relacionadas con Catéteres/microbiología , Infecciones Relacionadas con Catéteres/tratamiento farmacológico , Preescolar , Lactante , Infecciones por Bacterias Gramnegativas/tratamiento farmacológico , Infecciones por Bacterias Gramnegativas/microbiología , Infecciones por Bacterias Gramnegativas/epidemiología , Adolescente
6.
Jpn J Infect Dis ; 72(3): 185-192, 2019 May 23.
Artículo en Inglés | MEDLINE | ID: mdl-30700655

RESUMEN

In Turkey, the Measles Elimination Program has been implemented since 2002. The aim of this study was to evaluate the measles-specific antibody levels of mothers admitted to a hospital for birth and their infants, to determine the factors influencing the antibody levels of both, and to evaluate the transplacental transport ratio. We selected healthy women who came to the hospital for birth and their healthy newborns. We collected blood samples from 1,547 mothers and 1,529 infants. The protective prevalence of measles antibody levels of mothers was 80% (95% confidence interval [CI]: 78-82%) and that of newborns was 85% (95% CI: 83-86%). The antibody levels of mothers and newborns were positively linearly correlated (R: 0.922, p < 0.001) and were associated with parity (p < 0.001). The ratio of neonatal to maternal antibody levels increased with gestational age. The protective levels were 1.6 times higher (95% CI: 1.1-2.4) in mothers ≥ 32 years of age and 2.1 times higher (95% CI: 1.4-3.3) in naturally immune mothers. Two factors affecting the antibody levels of newborns were the mothers' antibody levels and their immunization status. The antibody level of mother was the most significant factor that influenced the infant's antibody level. Vaccination of women before pregnancy could enhance passive antibody protection by increasing the level of transplacental transmission.


Asunto(s)
Inmunidad Materno-Adquirida/inmunología , Vacuna Antisarampión/inmunología , Virus del Sarampión/inmunología , Sarampión/inmunología , Adulto , Anticuerpos Antivirales/sangre , Femenino , Sangre Fetal , Hospitales , Humanos , Inmunoglobulina G/sangre , Recién Nacido/inmunología , Intercambio Materno-Fetal , Sarampión/prevención & control , Madres , Embarazo , Prevalencia , Análisis de Regresión , Encuestas y Cuestionarios , Turquía , Adulto Joven
7.
Infect Dis (Lond) ; 47(7): 465-71, 2015 Jul.
Artículo en Inglés | MEDLINE | ID: mdl-25742190

RESUMEN

BACKGROUND: Cytomegalovirus (CMV) infections are the leading cause of infectious hearing loss and central nervous system disease among children worldwide. In this study, we aimed to determine the birth prevalence of congenital CMV infection in live-born infants in Turkey. METHODS: In total, 944 consecutive live-born infants born from 926 pregnant women were included in this study. CMV-DNA was investigated in saliva samples of all newborns within the first 3 days after birth using TaqMan-based real-time PCR. RESULTS: The birth prevalence of congenital CMV infection in live-born infants was 1.91% (18/944), and all congenitally infected infants were asymptomatic at birth. The prevalence of congenital CMV infection was 16.7% (3/18) in twin pregnancies and 1.32% (12/908) in single pregnancies (p = 0.002). Genotyping analysis showed glycoprotein B-1 (gB1) to be the most frequently detected genotype at 83.3%. CONCLUSION: The study results suggest that the majority of congenital CMV infection in Turkey occurs following nonprimary maternal infection. We believe that congenital CMV infection and its long-term effects have been underestimated in our country, as infected infants are usually asymptomatic at birth.


Asunto(s)
Infecciones por Citomegalovirus/congénito , Infecciones por Citomegalovirus/epidemiología , Citomegalovirus/genética , Proteínas del Envoltorio Viral/genética , Tasa de Natalidad , Citomegalovirus/clasificación , Citomegalovirus/aislamiento & purificación , Infecciones por Citomegalovirus/diagnóstico , Femenino , Humanos , Lactante , Recién Nacido , Embarazo , Embarazo Gemelar , Prevalencia , Turquía/epidemiología
8.
Chem Phys Lipids ; 184: 69-75, 2014 Dec.
Artículo en Inglés | MEDLINE | ID: mdl-25262585

RESUMEN

BACKGROUND/OBJECTIVE: Cytokines released from the adipose tissue and fatty acids (FAs) derived from lipolysis or uptake of fats go in to competition with glucose to be uptaken from the liver leads to insulin resistance (IR). We aimed to show the associations among serum lipid profile, FA compositions and IR. METHODS: Anthropometrical measurements, biochemical parameters and erythrocyte membrane (EM) FA levels of 95 obese adolescents (41 with IR) and 40 healthy controls were compared. RESULTS: LDL-C, fasting insulin levels, HOMA-IR were significantly higher and HDL-C levels were significantly lower in obese patients than in controls (p=0.013, p<0.001, p<0.001 and p<0.001, respectively). EM C 24:0, C 16:1 ω7 and C 22:1 ω9 FA levels were significantly higher, while C 20:5 ω3 (EPA) levels were significantly lower in obese subjects than in controls (p<0.001, p=0.018, p<0.001, p=0.043 and p<0.001, respectively). Moreover, when obese subjects divided into two groups according to the presence of IR; EM C 16:1 ω7 levels were still significantly higher and EPA levels were still significantly lower in both obese subjects with and without IR compared to controls (p<0.001 for both). CONCLUSION: Saturated FA intake should be decreased because of its role in the development of obesity and IR, and ω-3 group FA intake should be increased.


Asunto(s)
Cromatografía de Gases , Membrana Eritrocítica/química , Ácidos Grasos/sangre , Resistencia a la Insulina , Obesidad/patología , Adolescente , Adulto , Área Bajo la Curva , Índice de Masa Corporal , Niño , HDL-Colesterol/sangre , LDL-Colesterol/sangre , Ácidos Grasos Omega-3/sangre , Ácidos Grasos Omega-6/sangre , Ácidos Grasos Insaturados/sangre , Femenino , Humanos , Insulina/sangre , Masculino , Obesidad/metabolismo , Curva ROC
SELECCIÓN DE REFERENCIAS
DETALLE DE LA BÚSQUEDA